MX360289B - Composiciones de tapentadol. - Google Patents

Composiciones de tapentadol.

Info

Publication number
MX360289B
MX360289B MX2015001087A MX2015001087A MX360289B MX 360289 B MX360289 B MX 360289B MX 2015001087 A MX2015001087 A MX 2015001087A MX 2015001087 A MX2015001087 A MX 2015001087A MX 360289 B MX360289 B MX 360289B
Authority
MX
Mexico
Prior art keywords
analgesic
effective amount
therapeutically effective
tramadol
nsaid
Prior art date
Application number
MX2015001087A
Other languages
English (en)
Inventor
Sesha Ramesh
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX360289B publication Critical patent/MX360289B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Adhesive Tapes (AREA)

Abstract

La presente invención se refiere a un método para tratar dolor y condiciones relacionadas con dolor al administrar a un paciente en necesidad de lo mismo, una cantidad terapéuticamente efectiva de un hidrocloruro de Tapentadol de liberación lenta y una cantidad terapéuticamente efectiva de un segundo analgésico, en donde el segundo analgésico es tramadol. análogo de ácido gamma-aminobutírico (GABA) o un NSAID. La presente invención proporciona además una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de un hidrocloruro de Tapentadol de liberación lenta y una cantidad terapéuticamente efectiva de un segundo analgésico, en donde el segundo analgésico es tramadol, análogo de ácido gamma-aminobutírico (GABA) o un NSAID.
MX2015001087A 2007-11-23 2008-11-21 Composiciones de tapentadol. MX360289B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US402907P 2007-11-23 2007-11-23
PCT/US2008/084423 WO2009067703A2 (en) 2007-11-23 2008-11-21 Tapentadol compositions

Publications (1)

Publication Number Publication Date
MX360289B true MX360289B (es) 2018-10-29

Family

ID=40263271

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010005680A MX2010005680A (es) 2007-11-23 2008-11-21 Composiciones de tapentadol.
MX2015001087A MX360289B (es) 2007-11-23 2008-11-21 Composiciones de tapentadol.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2010005680A MX2010005680A (es) 2007-11-23 2008-11-21 Composiciones de tapentadol.

Country Status (24)

Country Link
US (3) US20100297229A1 (es)
EP (3) EP2219633A2 (es)
JP (1) JP5774850B2 (es)
KR (3) KR101607112B1 (es)
CN (3) CN102908339A (es)
AU (1) AU2008328548B2 (es)
BR (1) BRPI0819451A2 (es)
CA (1) CA2706596A1 (es)
CY (1) CY1118672T1 (es)
DK (1) DK2596784T3 (es)
ES (1) ES2619329T3 (es)
HR (1) HRP20170424T1 (es)
HU (1) HUE031931T2 (es)
IL (1) IL205915A (es)
LT (1) LT2596784T (es)
MX (2) MX2010005680A (es)
NZ (2) NZ601529A (es)
PL (1) PL2596784T3 (es)
PT (1) PT2596784T (es)
RS (1) RS55769B1 (es)
RU (1) RU2497512C2 (es)
SI (1) SI2596784T1 (es)
WO (1) WO2009067703A2 (es)
ZA (1) ZA201003716B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4534077A1 (en) 2023-10-05 2025-04-09 Laboratorios Silanes, S.A. de C.V. Composition comprising cyanocobalamin, pyridoxine, thiamine, pregabalin and celecoxib

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CN102908339A (zh) * 2007-11-23 2013-02-06 格吕伦塔尔有限公司 他喷他多组合物
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
SI2735338T1 (sl) * 2008-09-05 2019-04-30 Grunenthal Gmbh Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol in pregabalina ali gabapentina
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
US8802681B2 (en) 2008-10-17 2014-08-12 Signature Therapeutics, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
BRPI1014720A2 (pt) * 2009-04-30 2016-04-12 Gruenenthal Gmbh uso de compostos de 1-fenil-3-dimetilaminopropano para o tratamento da dor reumatoide
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
TWI473628B (zh) 2009-07-22 2015-02-21 用於對氧化敏感之類鴉片藥劑之抗破壞劑型
JP5905872B2 (ja) 2010-04-07 2016-04-20 ルピン・リミテッド タペンタドールの制御放出医薬組成物
US20130059914A1 (en) 2010-04-21 2013-03-07 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
US9238020B2 (en) 2010-04-21 2016-01-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
EP2383255A1 (en) 2010-04-28 2011-11-02 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
EP2566461A2 (de) * 2010-05-05 2013-03-13 Ratiopharm GmbH Festes tapentadol in nicht-kristalliner form
SI2582366T1 (sl) * 2010-06-15 2016-02-29 Gruenenthal Gmbh Farmacevtska kombinacija za zdravljenje bolečine
AR082189A1 (es) * 2010-07-06 2012-11-21 Gruenenthal Gmbh Formas de dosificacion gastrorretentivas, procedimiento
EP3597628A1 (en) * 2010-07-23 2020-01-22 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
ES2584634T3 (es) 2011-01-11 2016-09-28 Signature Therapeutics, Inc. Composiciones que comprenden un profármaco de oxicodona escindible enzimáticamente
KR101946790B1 (ko) 2011-03-04 2019-02-13 그뤼넨탈 게엠베하 경구 투여를 위한 타펜타돌의 수성 약제학적 제형
CA2828635C (en) 2011-03-04 2020-01-14 Grunenthal Gmbh Parenteral administration of tapentadol
RS56692B1 (sr) * 2011-03-04 2018-03-30 Gruenenthal Gmbh Polučvrsta vodena farmaceutska kompozicija koja sadrži tapentadol
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
AU2012225337B2 (en) 2011-03-09 2016-04-28 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
RS58064B1 (sr) * 2011-04-05 2019-02-28 Gruenenthal Gmbh Tapentadol za sprečavanje hronifikacije bola
LT3272343T (lt) 2011-04-29 2020-05-11 Grünenthal GmbH Tapentadolis, skirtas depresijos ir nerimo prevencijai ir gydymui
EP2530072A1 (en) 2011-06-03 2012-12-05 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
AU2012289764B2 (en) 2011-07-29 2017-03-02 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
ES2648129T3 (es) 2011-07-29 2017-12-28 Grünenthal GmbH Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN102924303B (zh) * 2012-10-31 2013-11-20 合肥市新星医药化工有限公司 盐酸他喷他多晶型c及其制备方法和应用
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
MX362435B (es) * 2013-08-02 2019-01-17 Laboratorio Raam De Sahuayo S A De C V Novedoso sistema farmaceutico de entrega bifasica para el tratamiento del dolor y la inflamacion.
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
KR20160058944A (ko) * 2013-09-27 2016-05-25 존슨 앤드 존슨 컨수머 인코포레이티드 압축 코팅된 맥동성 방출 조성물
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
RU2545915C1 (ru) * 2014-02-14 2015-04-10 Олег Васильевич Рубальский Способ лечения хронического болевого синдрома
EP3142646A1 (en) * 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
MX2014008336A (es) 2014-07-07 2016-01-07 Pptm Internat S A R L Combinacion farmacologica antihiperalgesica, antialodinica y antiinflamatoria, composiciones farmaceuticas que la contienen, y su uso para el tratamiento del dolor neuropatico.
CN104188947A (zh) * 2014-08-26 2014-12-10 安徽省逸欣铭医药科技有限公司 盐酸他喷他多与右旋酮洛芬氨丁三醇的复方药物组合物
CN104434881A (zh) * 2014-11-20 2015-03-25 哈尔滨圣吉药业股份有限公司 一种盐酸他喷他多缓释微丸及其制备方法
EP3273953B1 (en) 2015-03-27 2019-01-02 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
ES2869981T3 (es) 2015-05-26 2021-10-26 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composiciones para su uso en el tratamiento de la enfermedad de parkinson y trastornos relacionados
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
CN109996533A (zh) 2016-09-23 2019-07-09 格吕伦塔尔有限公司 用于肠胃外施用他喷他多的稳定制剂
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic
WO2019122982A1 (en) 2017-12-21 2019-06-27 Grünenthal GmbH Pharmaceutical combination in a bilayer tablet form comprising ketorolac tromethamine and tramadol hydrochloride, and its use in pain treatment
MX2018013070A (es) 2017-12-29 2019-10-15 Gruenenthal Gmbh Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
WO2020051182A1 (en) * 2018-09-07 2020-03-12 Lohocla Research Corporation Analgesic compositions
MX2023006728A (es) * 2020-12-16 2023-06-19 New Frontier Labs Llc Esteres de acido dicarboxilico para inducir un efecto analgesico.
WO2022130290A1 (en) * 2020-12-16 2022-06-23 New Frontier Labs, Llc Dicarboxylic acid esters for the treatment of diseases and conditions associated with phospholipase d toxin
US12599578B2 (en) 2021-03-09 2026-04-14 Ensysce Biosciences Inc. Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof
MX2024003466A (es) 2021-09-29 2024-06-04 Ensysce Biosciences Inc Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos.
CN116253652A (zh) * 2021-12-09 2023-06-13 武汉思瓴生物科技有限公司 他喷他多的长链脂肪酸酯类衍生物、药学上可接受的盐、药物组合物及制备方法和应用
CN118403043A (zh) * 2022-12-30 2024-07-30 浙江理工大学 一种用于治疗关节炎的药物及其组合物的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4034758A (en) 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
CA1083044A (en) 1976-05-04 1980-08-05 Stewart Wong Antiarthritic potentiation
US4260629A (en) 1979-10-25 1981-04-07 E. I. Du Pont De Nemours And Company Treating pain with acetaminophen and 1,4-dimethyl-5-p-chlorobenzoyl-pyrrole-2-acetic acid
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4587252A (en) 1984-12-18 1986-05-06 Brighton Pharmaceutical, Inc. Hydrocodone/ibuprofen pharmaceutical compositions and method
US4571400A (en) 1984-12-18 1986-02-18 Belleview Pharmaceutical, Inc. Dihydrocodeine/ibuprofen pharmaceutical compositions and method
US4569937A (en) * 1985-02-11 1986-02-11 E. I. Du Pont De Nemours And Company Analgesic mixture of oxycodone and ibuprofen
US5071607A (en) 1990-01-31 1991-12-10 Alza Corporatino Method and apparatus for forming a hole in a drug dispensing device
AU657351B2 (en) * 1991-09-06 1995-03-09 Mcneilab, Inc. Compositions comprising a tramadol material and any of codeine, oxycodone or hydrocodone and their use
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
DE60022333T2 (de) * 1999-04-09 2006-07-06 Euro-Celtique S.A. Natrium kanalblocker zusammensetzungen und deren verwendung
US20030059466A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Delayed release tablet of venlafaxin
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
US20060099249A1 (en) * 2002-02-21 2006-05-11 Pawan Seth Modified release formulations of at least one form of tramadol
EP2987788A1 (en) * 2002-05-17 2016-02-24 Taiwanj Pharmaceuticals Co., Ltd. Opioid and opioid-like compounds and uses thereof
PT1562567T (pt) * 2002-11-22 2017-08-24 Gruenenthal Gmbh Combinação de analgésicos selecionados e inibidores da cox-ii
CN1832736A (zh) * 2003-08-05 2006-09-13 兰贝克赛实验室有限公司 加巴喷丁的稳定缓释口服剂型
TW200640497A (en) * 2005-01-21 2006-12-01 Pharmanova Inc Pharmaceutical formulations and methods of use
WO2007005716A2 (en) * 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
JP2009522294A (ja) * 2005-12-29 2009-06-11 デポメッド， インコーポレイテッド 胃保持型ガバペンチン投薬形態およびその使用方法
RU2442576C2 (ru) * 2006-04-28 2012-02-20 Грюненталь Гмбх Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол
CN105561311B (zh) * 2006-04-28 2019-07-16 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
US20070254960A1 (en) * 2006-04-28 2007-11-01 Gruenenthal Gmbh Pharmaceutical combination
CN102908339A (zh) * 2007-11-23 2013-02-06 格吕伦塔尔有限公司 他喷他多组合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4534077A1 (en) 2023-10-05 2025-04-09 Laboratorios Silanes, S.A. de C.V. Composition comprising cyanocobalamin, pyridoxine, thiamine, pregabalin and celecoxib

Also Published As

Publication number Publication date
KR101972299B1 (ko) 2019-08-16
ZA201003716B (en) 2011-02-23
CN104958282A (zh) 2015-10-07
KR101784777B1 (ko) 2017-11-06
AU2008328548A1 (en) 2009-05-28
US20170216212A1 (en) 2017-08-03
AU2008328548B2 (en) 2014-05-15
HRP20170424T1 (hr) 2017-06-16
EP2219633A2 (en) 2010-08-25
CA2706596A1 (en) 2009-05-28
CN102908339A (zh) 2013-02-06
RU2497512C2 (ru) 2013-11-10
WO2009067703A2 (en) 2009-05-28
KR20170116178A (ko) 2017-10-18
HUE031931T2 (en) 2017-08-28
IL205915A (en) 2015-08-31
US20140242169A1 (en) 2014-08-28
MX2010005680A (es) 2010-12-21
KR20160038066A (ko) 2016-04-06
CN102065852B (zh) 2015-06-17
KR101607112B1 (ko) 2016-03-29
PL2596784T3 (pl) 2017-06-30
CN102065852A (zh) 2011-05-18
CY1118672T1 (el) 2017-07-12
DK2596784T3 (en) 2017-03-06
ES2619329T3 (es) 2017-06-26
SI2596784T1 (sl) 2017-04-26
NZ601529A (en) 2014-06-27
LT2596784T (lt) 2017-03-27
NZ586361A (en) 2012-09-28
EP2596784B1 (en) 2016-12-21
CN104958282B (zh) 2018-05-29
EP2596784A1 (en) 2013-05-29
BRPI0819451A2 (pt) 2017-10-03
US20100297229A1 (en) 2010-11-25
HK1184371A1 (en) 2014-01-24
EP3170494A2 (en) 2017-05-24
PT2596784T (pt) 2017-03-29
RS55769B1 (sr) 2017-07-31
JP2011504509A (ja) 2011-02-10
EP3170494A3 (en) 2017-09-06
IL205915A0 (en) 2010-11-30
KR20100129264A (ko) 2010-12-08
RU2010123346A (ru) 2011-12-27
JP5774850B2 (ja) 2015-09-09
WO2009067703A3 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
MX360289B (es) Composiciones de tapentadol.
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
BRPI0514253A (pt) terapia de combinação para diabetes, obesidade e doenças cardiovasculares usando composições contendo inibidores de gdf-8
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
MX2012010161A (es) Metodo para tratar el mal de parkinson.
WO2008010222A3 (en) Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating cns disorders
PH12012500765A1 (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase
NO20076508L (no) Acyloksykarbamat prodroger av traneksaminsyre og fremgangsmater for fremstilling og anvendelse derav
NZ619076A (en) Isoxazolines as inhibitors of fatty acid amide hydrolase
NO20083885L (no) Fremgangsmate for behandling av inflammatoriske sykdommer
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
WO2008027350A3 (en) Acetaminophen pharmaceutical compositions
BR112012009376B8 (pt) composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica
WO2008157537A3 (en) Compositions and methods of use for treating or preventing lipid related disorders
WO2008124505A3 (en) Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
BR112014008036A2 (pt) tratamento de rinite
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
BRPI0720500A8 (pt) Preparação líquida transdérmica
NO341602B1 (no) Farmasøytisk kombinasjon omfattende 3-(3-dimetylamino-1-etyl-2-metyl-propyl)-fenol og paracetamol
SE0400184D0 (sv) New therapeutical use
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
BRPI0703970A2 (pt) tratamento de pacientes psiquiátricos com função hepática reduzida com paliperidona
WO2007143185A3 (en) Transdermal treatment of tendinopathy using glyceryl trinitrite
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease